MedTrace Logo

Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma

NCT05461235 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2022-07-18

No results posted yet for this study

Summary

This is a prospective, open, single-arm Phase II clinical study to evaluate the efficacy and safety of anti-PD-1 antibody combined with autologous DC and NK cells in the treatment of digestive carcinoma.

Conditions

  • PD-1 Antibody
  • DC-Cell
  • NK-Cell
  • Gastrointestinal Tumours

Interventions

DRUG

Pembrolizumab

2mg/kg or 200mg,iv,q3w

DRUG

Nivolumab

3mg/kg or 240mg,iv,q2w

DRUG

Sintilimab

200mg,iv,q3w

DRUG

Toripalimab

3mg/kg or 240mg,iv,q2w

DRUG

Camrelizumab

200mg,iv,q2w or q3w;3mg/kg,iv,q3w

DRUG

Tislelizumab

200mg,iv,q3w

BIOLOGICAL

NK-Cell or DC-Cell

50ml of peripheral blood was collected 1 day before the dosing cycle for in vitro isolation and amplification of DC and NK cells; the first transfusion of DC and NK cells (not less than 1x10\^6 cells/Kg) was completed on day 14.

Sponsors & Collaborators

  • China Medical University, China

    lead OTHER

Principal Investigators

  • Yunpeng Liu, PhD · First Hospital of China Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2025-07-15
Completion
2025-12-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05461235 on ClinicalTrials.gov